HUP9801677A2 - Béta-laktám antibiotikumot tartalmazó orális adagolás formák és eljárás azok előállítására - Google Patents

Béta-laktám antibiotikumot tartalmazó orális adagolás formák és eljárás azok előállítására

Info

Publication number
HUP9801677A2
HUP9801677A2 HU9801677A HUP9801677A HUP9801677A2 HU P9801677 A2 HUP9801677 A2 HU P9801677A2 HU 9801677 A HU9801677 A HU 9801677A HU P9801677 A HUP9801677 A HU P9801677A HU P9801677 A2 HUP9801677 A2 HU P9801677A2
Authority
HU
Hungary
Prior art keywords
weight
excipients
amount
oral dosage
lactam antibiotic
Prior art date
Application number
HU9801677A
Other languages
English (en)
Inventor
Gerrit Jan Sijbrands
Robertus Cornelis Van Koutrik
Original Assignee
Yamanouchi Europe B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Europe B.V. filed Critical Yamanouchi Europe B.V.
Publication of HUP9801677A2 publication Critical patent/HUP9801677A2/hu
Publication of HUP9801677A3 publication Critical patent/HUP9801677A3/hu
Publication of HU227938B1 publication Critical patent/HU227938B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

A találmány tárgya 50 és 99,9 tömeg% közötti mennyiségű, vízbenlegalább 1 : 10 arányban őldódó, őrálisan hatékőny b-laktámantibiőtikűmőt, 0 és 50 tömeg% közötti mennyiségű mikrőkristályőscellűlózt, mikrőfinőmságú cellűlózt vagy ezek elegyét, és 0 és 0,5tömeg% közötti mennyiségű nedves granűlálási kötőanyagőt tartalmazógranűlátűm, ahől a %-ős értékek a granűlátűmra vannak vőnatkőztatva,valamint az előállítására szőlgáló eljárás képezi, amelynél a) akőmpőnenseket megnedvesítik 0 és 0,5 tömeg% közötti mennyiségű nedvesgranűlásási kötőanyagőt tartalmazó vizes őldattal, b) a a nedvesmasszát átszitálják egy 2 mm lyűkméretű szitán, c) a kapőtt terméketmegszárítják, d) a kapőtt terméket átszitálják egy legalább 0,71 mmlyűkméretű szitán. A találmány tárgyát képezi tővábbá a fentigranűlátűmőt és egy vagy több, szétesést elősegítő anyagőt, adőttesetben édesítőszereket, ízanyagőkat és más segédanyagőkat tartalmazóőrális adagőlási főrma, valamint az előállítására szőlgáló eljárás,amelynél a granűlátűmőt összekeverik az említett segédanyagőkkal, ésaz így kapőtt elegyet tablettává sajtőlják, vagy kapszűlába vagytasakba töltik. ŕ
HU9801677A 1995-02-08 1996-02-08 Oral dosage-forms containing a beta-lactam antibiotic and process for producing them HU227938B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200313 1995-02-08
PCT/EP1996/000547 WO1996024337A1 (en) 1995-02-08 1996-02-08 ORAL DOSAGE-FORMS CONTAINING A β-LACTAM ANTIBIOTIC

Publications (3)

Publication Number Publication Date
HUP9801677A2 true HUP9801677A2 (hu) 1998-11-30
HUP9801677A3 HUP9801677A3 (en) 1999-05-28
HU227938B1 HU227938B1 (en) 2012-06-28

Family

ID=8220003

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801677A HU227938B1 (en) 1995-02-08 1996-02-08 Oral dosage-forms containing a beta-lactam antibiotic and process for producing them

Country Status (19)

Country Link
US (1) US5948422A (hu)
EP (1) EP0801559B1 (hu)
CN (1) CN1125636C (hu)
AT (1) ATE216576T1 (hu)
AU (1) AU4789696A (hu)
BG (1) BG63528B1 (hu)
BR (1) BR9607189A (hu)
CZ (1) CZ293718B6 (hu)
DE (1) DE69620866T2 (hu)
DK (1) DK0801559T3 (hu)
EA (2) EA000361B1 (hu)
ES (1) ES2175073T3 (hu)
HU (1) HU227938B1 (hu)
MX (1) MX9706062A (hu)
NO (1) NO319993B1 (hu)
PL (1) PL186386B1 (hu)
PT (1) PT801559E (hu)
WO (1) WO1996024337A1 (hu)
ZA (1) ZA961018B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
US6242006B1 (en) 1996-07-16 2001-06-05 Gist-Brocades B.V. β-lactam granules free of organic solvents
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
CA2322315C (en) * 1998-03-06 2008-09-16 Eurand International S.P.A. Fast disintegrating tablets
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
DE19922537A1 (de) * 1999-05-10 2000-11-16 Roland Bodmeier Darreichungsform zur Applikation in Körperöffnungen
AU2001288102A1 (en) * 2000-09-22 2002-04-02 Takeda Chemical Industries Ltd. Solid preparations
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
HUP0303178A3 (en) * 2001-02-05 2008-03-28 R P Scherer Technologies Methods and compositions for reducing the taste of pharmaceutically active agents
PL212421B1 (pl) * 2002-03-12 2012-09-28 Bristol Myers Squibb Co Kompozycja farmaceutyczna w postaci zawiesiny kwasowego leku i sposób jej wytwarzania oraz sposób maskowania gorzkiego lub innego nieprzyjemnego smaku leku
US8648065B2 (en) * 2002-10-02 2014-02-11 Meiji Seika Pharma Co., Ltd. Antibacterial medicinal composition of enhanced oral absorptivity
WO2004056363A2 (en) * 2002-12-20 2004-07-08 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
JP4926703B2 (ja) * 2003-07-03 2012-05-09 セルトリ・テクノロジーズ・エルエルシー セルトリ細胞および筋様細胞を含有する組成物、並びに細胞性移植における該組成物の使用
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
CA2626933C (en) * 2005-11-17 2015-12-29 Novartis Ag Pharmaceutical composition
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
AU2007278850B2 (en) * 2006-07-28 2013-06-06 Sertocell Biotechnology (Us) Corp. Adult sertoli cells and uses thereof
CA2736531C (en) * 2008-09-17 2016-10-25 Niconovum Ab Process for preparing snuff composition
EP2367422A4 (en) * 2008-12-17 2013-01-09 Altheus Therapeutics Inc FORMULAS FOR LAVATION
WO2023204773A1 (en) * 2022-04-20 2023-10-26 Bilim Ilac Sanayii Ve Ticaret A.S. Tablet formulations for the treatment of urinary system infections and method for the preparation of such formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3344030A (en) * 1964-06-15 1967-09-26 American Home Prod Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables
DE2251250C3 (de) * 1972-10-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung hochdosierter Antibiotica-Tabletten
DE2251249A1 (de) * 1972-10-19 1974-05-02 Hoechst Ag Verfahren zur herstellung von penicillin-verbindungen enthaltenden tabletten
EP0281200B1 (en) * 1987-03-02 1994-01-19 Yamanouchi Europe B.V. Pharmaceutical composition, pharmaceutical granulate and process for their preparation
US5049394A (en) * 1987-09-11 1991-09-17 E. R. Squibb & Sons, Inc. Pharmaceutical composition containing high drug load and method for preparing same
EP0330284B1 (en) * 1988-02-25 1994-07-27 Yamanouchi Europe B.V. Process for the preparation of a pharmaceutical granulate
US5643591A (en) * 1991-01-16 1997-07-01 Fmc Corporation Solid dosage forms
DE69525151T2 (de) * 1994-04-13 2002-08-14 Res Corp Technologies Inc Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin

Also Published As

Publication number Publication date
EA199700093A1 (ru) 1998-02-26
MX9706062A (es) 1997-10-31
EA199900205A1 (ru) 2000-06-26
EP0801559A1 (en) 1997-10-22
PL321567A1 (en) 1997-12-08
DE69620866D1 (de) 2002-05-29
BG101822A (en) 1998-04-30
CN1125636C (zh) 2003-10-29
ZA961018B (en) 1997-08-08
CN1173816A (zh) 1998-02-18
EA000361B1 (ru) 1999-06-24
HU227938B1 (en) 2012-06-28
BR9607189A (pt) 1997-11-11
AU4789696A (en) 1996-08-27
EA003736B1 (ru) 2003-08-28
NO973646L (no) 1997-09-11
DE69620866T2 (de) 2003-02-27
CZ293718B6 (cs) 2004-07-14
EP0801559B1 (en) 2002-04-24
NO319993B1 (no) 2005-10-10
WO1996024337A1 (en) 1996-08-15
BG63528B1 (bg) 2002-04-30
CZ230297A3 (en) 1997-11-12
NO973646D0 (no) 1997-08-07
ES2175073T3 (es) 2002-11-16
US5948422A (en) 1999-09-07
PL186386B1 (pl) 2004-01-30
HUP9801677A3 (en) 1999-05-28
PT801559E (pt) 2002-09-30
ATE216576T1 (de) 2002-05-15
DK0801559T3 (da) 2002-06-17

Similar Documents

Publication Publication Date Title
HUP9801677A2 (hu) Béta-laktám antibiotikumot tartalmazó orális adagolás formák és eljárás azok előállítására
HUP9801615A2 (hu) Szimetikon/vízmentes kalcium-foszfát-kompozíciók
BR0012250A (pt) Processo de fabricação de grânulos revestidos com gosto mascarado, e liberação imediata do princìpio ativo, grânulo revestido, comprimido multiparticulado de dissolução rápida e comprimido de hidrodispersibilidade rápida
HUP0000141A2 (hu) Eljárás legfeljebb 90 tömeg% gyógyhatású anyagot tartalmazó pelletek előállítására
WO1997038679A3 (en) Fast disintegrating oral dosage form
GB1421964A (en) Process for the production of sustained release pharmaceutical preparations
WO2001083439A3 (fr) NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
AU594202B2 (en) Spray dried acetaminophen
HUP9700004A2 (hu) Pozitív hidratáló eljárás édességek előállítására és az így előállított termék
AU2003288756A1 (en) Barium titanate and electronic parts using the material
DK1207164T3 (da) Fremgangsmåde til fremstilling af et pulver, der indeholder krystallinske maltitolpartikler
JPS51112499A (en) The formation of titanium tetrachloride
HUP9901350A2 (hu) Dezogesztrelt tartalmazó, szárazon granulált, sajtolt tabletták, előállításuk
WO2007052307A3 (en) Stable solid oral dosage forms of valsartan
CA2163111A1 (en) Process for the preparation of an oral solid dosage form containing diclofenac
CA2035841A1 (en) Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture
NO20004919L (no) Fremgangsmåte for fremstilling av 5-hydroksybenzo[b]tiofen-3- karboksylsyrederivater
WO2001070694A8 (en) Amorphous torasemide modification
ES8203793A1 (es) Un procedimiento para la preparacion de un peroxido de metalalcalino o metal alcalino-terreo
GB1424214A (en) Method for manufacturing filter for removing cadmium and cadmium compounds from gas and particularly intended for cigarettes
CA2713466A1 (en) Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
JPS51146400A (en) Process for production of cubic boron nitride
CA2352670A1 (en) Chewing gum with increased flavor release using an alginate material
JPS5212143A (en) Process for preparation of alpha-(4' -isobutylphenyl)alkylacetic acid
JPS5268188A (en) Preparation of 1-(tetrahydro-2-furyl)-5-fluorouracil

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: ASTELLAS PHARMA EUROPE B.V., NL

Free format text: FORMER OWNER(S): YAMANOUCHI EUROPE B.V., NL

MM4A Lapse of definitive patent protection due to non-payment of fees